Skip to content

Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Alzheimer Disease

A Phase II, Randomized, Blinded Study of Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for the Treatment of Chronic Aphasia - Alzheimer Disease Sub-study

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04482179
Enrollment
23
Registered
2020-07-22
Start date
2020-02-19
Completion date
2024-08-31
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Brief summary

Impaired verbal communication is a cardinal symptom of Alzheimer Disease (AD) and the source of enormous distress and disability. Effective therapies for this deficit are lacking. In light of the emerging literature demonstrating that Transcranial Magnetic Stimulation (TMS) improves general cognition in subjects with Alzheimer Disease (AD), the investigators propose to study the effectiveness of TMS as a therapy for impaired verbal communication. The hypothesis to be tested is that TMS combined with Constraint Induced Language Therapy (CILT) improves verbal communication more than sham TMS and CILT. A second aim is to use state-of-the-art neuroimaging to understand the mechanisms underlying any beneficial effect of the treatment.

Detailed description

TMS is a technique by which a brief electrical current is induced in brain tissue causing a brief suppression of the excitability of the underlying tissue; the technique, which was introduced in the 1980s and has been extensively used around the world, has been shown to transiently improve or disrupt specific cognitive operations. To achieve this end, a coil is positioned against the subject's head. The delivery of a single pulse begins with the discharge of current from a capacitor into a circular or figure-of-eight coil; this electrical current generates a brief magnetic field of up to 2.2 Tesla. As the pulse of electricity has a rise time of 0.2 ms. and a duration of 1 ms., the magnetic field changes in intensity quite rapidly. Because the magnetic field passes freely through the scalp, skull, and meninges, the flux in the magnetic field induces a small electric field in the brain that transiently alters neural activity. TMS may be delivered in a variety of ways. The investigators propose to use 10 Hz TMS; that is, TMS pulses will be delivered at a frequency of 10/second, for a total of 1200 pulses. Using the figure-of-eight coil to be employed here, TMS is thought to affect activity in approximately 1 cubic cm. of cortex. Many investigators have employed TMS for AD with a frequency of 10 Hz and most have delivered 1200 pulses per session. The baseline phase will consist of 3 sessions, each lasting 1-2 hours depending on the stamina of the subject. The point of the baseline testing is to characterize the subject's language function. To that end, a number of standard language and neuropsychological tasks will be administered. These include the Western Aphasia Battery, Pyramids and Palm Trees test, Figural Fluency Test, word and non-word repetition tasks, spontaneous narrative production, CILT stimulus naming, and the Repeatable Battery for the Assessment of Neuropsychological Status. Additionally, during the baseline, subjects will undergo MRI of the brain or, if they have a contraindication to MRI, a CAT scan of the head. No contrast will be used. In the treatment phase, there will be 10 TMS sessions over 2 consecutive weeks in which 30 two-second stimulation trains of 10 Hz TMS will be delivered every 30 seconds to the left inferior pars triangularis and to the left posterior superior left temporal gyrus at 100% motor threshold. There will be a total of 600 pulses to each site in each session for a total of 1200 pulses per session. Each TMS treatment session will be immediately followed by a 60-90 minute session of CILT. There will be two 3-month post-treatment visits and two 6-month post-treatment visits in which the full battery of language and cognitive assessments will be repeated. Subjects who are able to undergo MRI scanning will have anatomic and fMRI scans at the first 6-month post-treatment visit. The investigators will pair TMS with CILT which has been shown to have positive outcomes in post-stroke aphasia. CILT invokes use-dependent learning in communicative interactions by requiring spoken output and restricting use of alternative forms of communication, such as gestures. The investigators will use a dual card-matching task modeled after Maher et al. As in the original CILT design, the participant interacts verbally with a conversational partner (here, the speech language pathologist), in turn requesting a card of given description and complying with the partner's request. In this way, the treatment targets both production and comprehension. Moreover, as verbal targets increase in linguistic complexity across the protocol (a ball, throw a ball; Do you have a ball?), a variety of lexical and phrasal structures are targeted. Studies of CILT have reported gains on multiple language behaviors, supporting its broad engagement of the language network.

Interventions

Active TMS will be delivered at 100% motor threshold

BEHAVIORALCILT

60-90 minutes of CILT will be administered during each treatment session

DEVICESham TMS

Sham TMS will be administered

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
National Institute on Deafness and Other Communication Disorders (NIDCD)
CollaboratorNIH
University of Pennsylvania
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

The individual administering TMS will keep the master file of subject assignments, but all other individuals in contact with the subject or their data will be unaware of group assignment. Participants will not be informed of their assignment to active or sham status.

Intervention model description

Participants will be randomized to either TMS or sham TMS in a 2:1 allocation ratio.

Eligibility

Sex/Gender
ALL
Age
60 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* A diagnosis of mild-moderate AD as defined by the National Institute of Aging - Alzheimer's Disease and Related Disorders Association criteria * Mild-moderate cognitive impairment, indicated by Mini-Mental Status Exam (MMSE) scores between 23 and 15 inclusive * Must be right handed as defined by the Edinburgh Handedness Inventory * Must be a native English speaker * Must be able to understand the nature of the study, and give informed consent

Exclusion criteria

* History of stroke * History of seizure * History of any other significant neurologic disease (e.g., ALS) * Significant depression as defined by the Geriatric Depression Scale. * Any significant medical disorder that, in the view of the investigators, could threaten the subject's ability to complete the study (e.g., cancer, significant cardiac disease) * Any contraindications to TMS, including uncontrolled seizures, previous brain surgery, and history of tinnitus

Design outcomes

Primary

MeasureTime frameDescription
Change in WAB-AQ Score12 weeks post-treatmentThe primary outcome measure will be the change in score on the Western Aphasia Battery Aphasia Quotient (WAB-AQ), a score assessing overall aphasia recovery. Scores can range from 0-100, with higher scores representing better outcomes. 0-25 is very severe, 26-50 is severe, 51-75 is moderate, and 76-above is mild. A score of 93 or higher is considered recovered.

Secondary

MeasureTime frameDescription
Change in Percentage of Items Correct on the PNT12 weeks post-treatmentThe secondary outcome measure will be change in naming accuracy on the Philadelphia Naming Test (PNT). PNT naming accuracy is measured as a percentage from 0% to 100% with higher percentages meaning better naming ability. The task involves naming 175 pictures of common objects.

Countries

United States

Participant flow

Recruitment details

Participants were recruited from 2019-2021 from the Hospital of the University of Pennsylvania and surrounding Philadelphia area medical centers.

Pre-assignment details

A total of 11 participants did not qualify at the time of enrollment due to MMSE scores (8) and medical contraindication (3). One participant dropped out of the study prior to randomization due to travel concerns.

Participants by arm

ArmCount
Active TMS
Participants will receive 10 TMS sessions over 2 consecutive weeks in which 20 minutes of TMS will be delivered to the left inferior pars triangularis and to the left posterior superior left temporal gyrus. Each TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
7
Sham TMS
Participants will take part in 10 sham TMS sessions over 2 consecutive weeks. Sham TMS mimics the sensory experience (look, sound and feel) of active TMS but does not stimulate the brain. Sham TMS will be administered with a sham TMS coil that looks and sounds like the active coil but does not generate a magnetic field. The sham TMS will target the same two brain locations - left inferior pars triangularis and the left posterior superior left temporal gyrus. Each sham TMS treatment session will be immediately followed by a 60-90 minute session of Constrained Induced Language Therapy (CILT).
4
Total11

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDeath10
Overall StudyWithdrawal by Subject10

Baseline characteristics

CharacteristicActive TMSSham TMSTotal
Age, Continuous70.1 years
STANDARD_DEVIATION 3.66
73.4 years
STANDARD_DEVIATION 1.76
71.27 years
STANDARD_DEVIATION 3.49
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
6 Participants2 Participants8 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants2 Participants3 Participants
Philadelphia Naming Test, Items Correct121.0 number of items correct
STANDARD_DEVIATION 37.6
157.3 number of items correct
STANDARD_DEVIATION 15.5
134.2 number of items correct
STANDARD_DEVIATION 35.4
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants2 Participants2 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
7 Participants2 Participants9 Participants
Sex: Female, Male
Female
3 Participants3 Participants6 Participants
Sex: Female, Male
Male
4 Participants1 Participants5 Participants
Western Aphasia Battery (WAB-AQ) Score80.7 scores on a scale
STANDARD_DEVIATION 7.8
87.4 scores on a scale
STANDARD_DEVIATION 6.1
83.1 scores on a scale
STANDARD_DEVIATION 7.7

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
1 / 70 / 4
other
Total, other adverse events
2 / 73 / 4
serious
Total, serious adverse events
1 / 70 / 4

Outcome results

Primary

Change in WAB-AQ Score

The primary outcome measure will be the change in score on the Western Aphasia Battery Aphasia Quotient (WAB-AQ), a score assessing overall aphasia recovery. Scores can range from 0-100, with higher scores representing better outcomes. 0-25 is very severe, 26-50 is severe, 51-75 is moderate, and 76-above is mild. A score of 93 or higher is considered recovered.

Time frame: 12 weeks post-treatment

ArmMeasureValue (MEAN)Dispersion
Active TMSChange in WAB-AQ Score-1.7 score on a scaleStandard Deviation 4.3
Sham TMSChange in WAB-AQ Score-.1 score on a scaleStandard Deviation 7.3
p-value: <0.05Regression, Linear
Secondary

Change in Percentage of Items Correct on the PNT

The secondary outcome measure will be change in naming accuracy on the Philadelphia Naming Test (PNT). PNT naming accuracy is measured as a percentage from 0% to 100% with higher percentages meaning better naming ability. The task involves naming 175 pictures of common objects.

Time frame: 12 weeks post-treatment

ArmMeasureValue (MEAN)Dispersion
Active TMSChange in Percentage of Items Correct on the PNT-3.2 percentage of correct responsesStandard Deviation 8.2
Sham TMSChange in Percentage of Items Correct on the PNT-5.0 percentage of correct responsesStandard Deviation 6.1
p-value: <0.05Regression, Linear

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026